Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest/Unilab

This article was originally published in The Gray Sheet

Executive Summary

Quest Diagnostics will submit more information on its proposed acquisition of diagnostic testing services firm Unilab following a request from the Federal Trade Commission. Completion of the $1.1 bil. purchase, first announced April 2, is expected to be delayed until the third quarter (1"The Gray Sheet" April 8, 2002, p. 19)...

You may also be interested in...



LabCorp Enhances Cancer Testing Capability With $600 Mil. Dianon Purchase

LabCorp says it does not foresee antitrust issues with the Federal Trade Commission related to the acquisition of cancer testing firm Dianon

Quest Diagnostics Spends $1.6 Bil. To Expand Presence In California, D.C.

Quest Diagnostics will control 12% of the $3.8 bil. California lab testing market following the acquisition of Unilab Corp. The $1.1 bil. deal was announced April 2, one day after Quest completed its $500 mil. cash acquisition of Amercian Medical Labs (AML)

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel